Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Onyx Starts Acquisition Process; Price And Competition To Come Into Play

This article was originally published in The Pink Sheet Daily

Executive Summary

The fast-growing biotech is soliciting bids, after a rejected Amgen offer and additional third party interest. Wall Street is scrambling to determine how to value Onyx and who the bidders could be.


Related Content

Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
Amgen’s $125 Per Share Offer For Onyx Reflects Kyprolis Uncertainty
Deals Of The Week: Tire-Kicking Season Continues Full-Swing
Quest Diagnostics’ Retrenchment Gives Royalty Pharma A Stake In Ibrutinib
Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace
Bayer Oncology Keystone Nexavar Looks Good For Thyroid Indication
Pfizer Oncology: Big Strides But Not Blockbuster Size
Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back
Onyx’s Transformative Year: From Productive Partner To Big Cap Contender?
With Kyprolis Advancing, Millennium Stakes Faith In Oral Velcade Successor


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts